



CS/BSE/UFR/2014-15
November 14, 2014

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
Bombay Stock Exchange Ltd
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,

Sub: Notification of Un-audited Financial Results for the quarter /six months ended September 30, 2014 – Clause 41

.....

With reference to the above subject, we are forwarding here with **Un-audited Financial Results of our Company for quarter /six months ended 30th September, 2014** in the prescribed proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-audited Financial Results for the second quarter in its meeting held on 14th November, 2014 and **Limited Review Report of Auditors of the Company**.

Please find enclosed Press release of our company. We request you to take these documents on your records.

Thanking you,
Yours faithfully,
For Suven Life Sciences Limited

K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: investorservices@suvlen.com website: www.suvlen.com

STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30th September, 2014

PART - I

Rs. in lakhs

Sl. No.	PARTICULARS	Quarter ended			Six Months ended		Previous year ended
		30/09/2014	30/06/2014	30/09/2013	30/09/2014	30/09/2013	31/03/2014
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Income from operations						
	(a) Net sales/income from operations (Net of excise duty)	13,983.12	14,153.16	15,141.23	28,136.28	26,008.19	51,031.24
	(b) Other operating income	-	-	-	-	-	-
	Total income from operations (net) (a)+(b)	13,983.12	14,153.16	15,141.23	28,136.28	26,008.19	51,031.24
2	Expenses						
	a) Cost of materials consumed	4,068.03	4,695.34	4,200.48	8,763.37	7,575.03	15,049.65
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,078.07	(47.88)	(727.64)	2,030.19	(712.95)	(1,397.66)
	d) Employee benefits expense	781.19	911.37	759.79	1,692.56	1,539.62	3,144.21
	e) Depreciation and amortisation expense	248.08	238.86	221.92	486.94	431.40	883.74
	f) Other expenses - Manufacturing Expenses	1,552.85	1,439.61	1,288.32	2,992.46	2,447.83	5,388.94
	- R & D Expenses	1,098.72	894.89	1,789.79	1,993.61	2,583.66	4,794.79
	- Others	565.29	471.67	689.27	1,036.96	1,130.59	2,145.45
	Total expenses	10,392.23	8,603.86	8,221.93	18,996.09	14,995.18	30,009.12
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	3,590.89	5,549.30	6,919.30	9,140.19	11,013.01	21,022.12
4	Other Income	141.98	107.94	11.41	249.92	326.94	302.95
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	3,732.87	5,657.24	6,930.71	9,390.11	11,339.95	21,325.07
6	Finance costs	132.99	116.42	341.28	249.41	660.34	1,051.28
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	3,599.88	5,540.82	6,589.43	9,140.70	10,679.61	20,273.79
8	Exceptional Items (Ref: Note No.4 below)	322.06	405.99	-	728.05	-	-
9	Profit/Loss from Ordinary Activities before tax (7+8)	3,277.82	5,134.83	6,589.43	8,412.65	10,679.61	20,273.79
10	Tax Expenses	794.17	1,661.01	2,034.75	2,455.18	3,147.74	5,858.04
11	Net Profit/ (Loss) from Ordinary Activities after tax (9-10)	2,483.65	3,473.82	4,554.68	5,957.47	7,531.87	14,415.75
12	Extraordinary Items (net of tax expense Rs____)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	2,483.65	3,473.82	4,554.68	5,957.47	7,531.87	14,415.75
14	Share of profit / (loss) of associates	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	2,483.65	3,473.82	4,554.68	5,957.47	7,531.87	14,415.75
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,168.29	1,168.29	1,168.29	1,168.29	1,168.29	1,168.29
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	25,276.34
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	2.13	2.97	3.90	5.10	6.45	12.34
	b) Diluted	2.13	2.97	3.90	5.10	6.45	12.34
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	2.13	2.97	3.90	5.10	6.45	12.34
	b) Diluted	2.13	2.97	3.90	5.10	6.45	12.34

PART - II		30/09/2014	30/06/2014	30/09/2013	30/09/2014	30/09/2013	31/03/2014
A	PARTICULARS OF SHAREHOLDING	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Public share holdings						
	a. Number of shares	41,171,212	41,171,212	41,171,212	41,171,212	41,171,212	41,171,212
	b. Percentage of share holding	35.24%	35.24%	35.24%	35.24%	35.24%	35.24%
2	Promoters and promoter group Shareholding						
	a) Pledged / Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered						
	- Number of shares	75,657,576	75,657,576	75,657,576	75,657,576	75,657,576	75,657,576
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	64.76%	64.76%	64.76%	64.76%	64.76%	64.76%
	Particulars	3 months ended (30/09/2014)					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	-					
	Received during the quarter	82					
	Disposed of during the quarter	82					
	Remaining unresolved at the end of the quarter	-					


SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

	PARTICULARS	Quarter ended			Six Months ended		Previous year ended
		30/09/2014	30/06/2014	30/09/2013	30/09/2014	30/09/2013	31/03/2014
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	SEGMENT REVENUE						
	a) Manufacturing (CRAMS)	13,006.64	13,894.85	14,742.29	26,901.59	25,430.81	49,344.00
	b) Services (DDDSS)	976.48	258.21	398.95	1,234.69	577.38	1,687.24
	c) Research & Development	-	-	-	-	-	-
	Net sales/income from operations	13,983.12	14,153.06	15,141.24	28,136.28	26,008.19	51,031.24
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)						
	a) Manufacturing (CRAMS)	4,300.75	6,731.05	8,859.93	11,031.80	14,039.63	26,308.56
	b) Services (DDDSS)	737.95	34.89	213.02	772.84	228.85	888.72
	c) Research & Development	(1,347.49)	(1,241.35)	(1,789.79)	(2,588.84)	(2,583.66)	(4,794.79)
	TOTAL	3,691.21	5,524.59	7,283.16	9,215.80	11,684.82	22,402.49
	Less: (i) Interest	81.87	77.56	194.13	159.43	411.56	618.92
	(ii) Other Un-allocable expenses net off	331.52	312.20	499.60	643.72	593.64	1,509.78
	(iii) un-allocable Income	-	-	-	-	-	-
	Profit Before Tax	3,277.82	5,134.83	6,589.43	8,412.65	10,679.62	20,273.79
3	CAPITAL EMPLOYED (Segment Assets-Segment Liabilities)						
	a) Manufacturing (CRAMS)	24,305.89	20,879.49	21,096.25	24,305.89	21,096.25	17,807.16
	b) Services (DDDSS)	3,211.14	3,322.55	3,203.02	3,211.14	3,203.02	3,434.62
	c) Research & Development	1,377.68	927.47	1,807.03	1,377.68	1,807.03	1,460.97
	d) Net assets which are not segmented and unallocable	9,912.25	10,568.80	4,169.47	9,912.25	4,169.47	10,453.81
	TOTAL	38,806.96	35,698.31	30,275.77	38,806.96	30,275.77	33,156.56

Notes:

- 1) The above Un-audited results were approved and taken on record at the Board of Directors' Meeting held on 14th November, 2014.
- 2) Previous year(s) figures have been regrouped/reclassified whenever necessary.
- 3) The above results are reviewed by Statutory Auditors.
- 4) The depreciation has been computed as per Schedule II of the Companies Act 2013 effective April 1, 2014. Accordingly the depreciation which is higher as shown as exceptional item under SI No. 8 above. Further, based on transitional provision in note 7(b) of schedule II an amount of **Rs. 473.50 Lakhs** (net of deferred tax of **Rs. 243.81 Lakhs**) has been adjusted with the opening Reserves.

For SUVEN LIFE SCIENCES LTD



VENKAT JASTI
Chairman & CEO

Place : Hyderabad
Date: 14th November, 2014

We Deliver



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Standalone Statement of Assets & Liabilities as per Clause 41(V)(h) as per Listing agreement

(Rs. In lakhs)

	Particulars	Half year Ended	
		30/09/2014	31/03/2014
A	EQUITY AND LIABILITIES		
1	Shareholder's funds:		
	(a) Share Capital	1,168.29	1,168.29
	(b) Reserves and Surplus	30,760.29	25,276.34
	Sub-total - Shareholders' funds	31,928.58	26,444.63
2	Non-current liabilities		
	(a) Long-term borrowings	4,372.55	3,772.92
	(b) Deferred tax Liability (net)	2,326.46	2,759.66
	(c) Long-term provisions	179.36	179.36
	Sub-total - Non-current liabilities	6,878.37	6,711.94
3	Current liabilities		
	(a) Short-term borrowings	2,498.96	2,855.36
	(b) Trade payables	3,350.11	4,090.05
	(c) Other current liabilities	3,874.57	4,751.84
	(d) Short-term provisions	2,015.52	3,808.90
	Sub-total - Current liabilities	11,739.16	15,506.15
	TOTAL - EQUITY AND LIABILITIES	50,546.11	48,662.72
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	21,341.96	19,205.41
	(b) Non-current investments	0.15	0.15
	(c) Deferred tax assets (net)	-	-
	(d) Long-term loans and advances	2,013.89	1,258.74
	Sub-total - Non-current assets	23,356.00	20,464.30
2	Current assets		
	(a) Current investments	5,228.96	3.64
	(b) Inventories	6,100.49	7,862.87
	(c) Trade receivables	6,064.12	6,547.03
	(d) Cash and cash equivalents	2,486.12	6,939.96
	(e) Short-term loans and advances	7,307.40	6,809.17
	(f) Other current assets	3.02	35.75
	Sub-total - Current assets	27,190.11	28,198.42
	TOTAL - ASSETS	50,546.11	48,662.72

For Suven Life Sciences Ltd

Venkat Jasti
Chairman & CEO



Ref No.LR/006/2014-15:

LIMITED REVIEW REPORT

To

The Board of Directors of
M/s. SUVEN LIFE SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/S. SUVEN LIFE SCIENCES LIMITED, having registered office at 8-2-334, 6th Floor, SDE Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 34, for the period ended on 30.09.2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India*. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for KARVY & CO.,
Chartered Accountants
(Registration No.001757S)


(K. AJAY KUMAR)
P A R T N E R
M.No.021989



Place: Hyderabad
Date : 14/11/2014



News Release

Suven Revenue growth at 7.8% while PAT is down by 20% for the half year ended September, 2014

HYDERABAD, INDIA (14th November 2014) – SUVEN Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2014. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Nov' 2014 at Hyderabad.

Financial Highlights for the 2nd Quarter ended September' 2014:

Growth in revenue	Rs 1412 Mn vs Rs 1515 Mn	- down by 6.8%
Growth in PAT	Rs 248 Mn vs. Rs 455 Mn	- down by 45%
Growth in EBITDA	Rs 398 Mn vs. Rs 715 Mn	- down by 44 %

Financial Highlights for the Half year ended September' 2014:

Growth in revenue	Rs 2839 Mn vs Rs 2633 Mn	- up by 7.8%
Growth in PAT	Rs 596 Mn vs. Rs 753 Mn	- down by 20%
Growth in EBITDA	Rs 715 Mn vs. Rs 1177 Mn	- down by 22%

PAT for the current quarter was reduced by Rs. 32.2 Mn & for the Half year reduced by Rs.72.8 Mn due to charge of additional depreciation computed as per Schedule II of the Companies Act 2013 effective April 1, 2014, shown as exceptional item in Profit & Loss Account. If the similar provisions of same quarter of previous years followed the PAT for this quarter would have been higher by Rs. 32.2 Mn to Rs 280.2 million and PAT for the half year would have been higher by Rs.72.8 million to Rs 668.8 million

Lower revenue and PAT during this quarter compared to the same quarter last year is due to the absence of pre-launch supplies of intermediates for 3 of the NCE's which were done last year. The repeat order for these supplies may happen after a gap of 12-18 months.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 259 Mn (7.02% on revenue) for the half year ended Sept' 2014.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com